Amphastar Pharmaceuticals (AMPH) Operating Margin (2013 - 2026)
Amphastar Pharmaceuticals' (AMPH) quarterly Operating Margin came in at 7.96% in Q1 2026, down 1391.0% year-on-year from 0.62% in Q1 2025, and down 59.05% quarter-over-quarter from 19.45% in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Operating Margin (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Operating Margin history runs 14 years deep, the most recent figure standing at 7.96% for Q1 2026.
- On a quarterly basis, Operating Margin fell 1391.0% year-over-year to 7.96% in Q1 2026; TTM through Mar 2026 was 16.2%, a 1045.0% decrease from a year earlier, with the FY2025 full-year figure at 19.5%, down 856.0% from the prior year.
- Operating Margin retreated to 7.96% in Q1 2026 per AMPH's latest filing, from 19.45% in the prior quarter.
- Across five years, Operating Margin topped out at 40.25% in Q3 2023 and bottomed at 7.96% in Q1 2026.
- The 5-year median for Operating Margin is 24.19% (2025), against an average of 23.77%.
- Across the five-year window, Operating Margin soared 2092 bps in 2023 and plunged 1664 bps in 2025, its largest moves.
- Year by year, Operating Margin stood at 28.02% in 2022, then increased by 8 bps to 30.31% in 2023, then fell by 20 bps to 24.2% in 2024, then decreased by 20 bps to 19.45% in 2025, then sank by 59 bps to 7.96% in 2026.
- Per Business Quant, the three latest AMPH Operating Margin figures stand at 7.96% (Q1 2026), 19.45% (Q4 2025), and 13.2% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Amphastar Pharmaceuticals | 855.23 Mn | 684.09 Mn | 70.32 Mn | 7.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.96% |
| Dec 31, 2025 | 19.45% |
| Sep 30, 2025 | 13.20% |
| Jun 30, 2025 | 24.19% |
| Mar 31, 2025 | 21.87% |
| Dec 31, 2024 | 24.20% |
| Sep 30, 2024 | 29.83% |
| Jun 30, 2024 | 30.27% |
| Mar 31, 2024 | 27.94% |
| Dec 31, 2023 | 30.31% |
| Sep 30, 2023 | 40.25% |
| Jun 30, 2023 | 25.32% |
| Mar 31, 2023 | 23.88% |
| Dec 31, 2022 | 28.02% |
| Sep 30, 2022 | 19.34% |
| Jun 30, 2022 | 20.10% |
| Mar 31, 2022 | 17.96% |
| Dec 31, 2021 | 20.06% |
| Sep 30, 2021 | 22.08% |
| Jun 30, 2021 | 10.39% |